Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.

World J Diabetes · 2021 · PMC8696643 · PMID 35047122

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = 0.06so close (0.05 < p ≤ 0.1)

While the present study is not definitive and did not reach statistical significance ( P = 0.06), it demonstrates a decrease from baseline in mean HbA1c after switching patients from sitagliptin to omarigliptin exists and sets a precedent for future studies.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.